We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.625 | 6.25 | 7.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCOS
RNS Number : 1695D
Collagen Solutions PLC
25 April 2017
Collagen Solutions Plc
(the "Company" or the "Group")
Preliminary FY 2017 revenue and other income of GBP4.1 Million
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces preliminary revenue, including other income, of GBP4.1 million for the year ending 31 March 2017 (GBP3.2m in 2016), of which approximately GBP3.95 million was trading revenue, representing 26% growth.
This growth has been driven by an increase in the number of customers, higher volumes from key customers and an increase in new development agreements. In particular, the Company has seen its pericardium tissue business grow by 30% resulting in a specific initiative to diversify and increase its tissue supply base in Australia and New Zealand to meet the additional demand.
Investments in the Company's commercial organisation have also begun to show results, with the team delivering nine new supply, development and distribution agreements during the financial year, including the recently announced Smart Matrix deal. These should provide future recurring revenues, as customers transition from development to full launch supply. Due to long sales cycles and timing of appointments to the new sales team, the majority of these agreements were closed in the second half of the year. Consequently, these agreements did not contribute materially to the 2016 revenue growth.
Jamal Rushdy, CEO of Collagen Solutions commented: "We are on track with the commercial plans for our core business. The investment that we have made in the commercial team is showing results and we are starting to see improved volume, value, and pace of origination in our pipeline of opportunities. We are also seeking to capitalise on the greater demand for pericardium that we are seeing and have implemented the appropriate operational focus to ensure we can support expected growth in this segment as well. Following the successful fundraising last month, we have also continued to make progress with our product development pipeline and I will update you on this over the coming months."
The Company will announce its financial results for the year ending 31 March 2017 on 11 July 2017.
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R), an osteochondral scaffold for repairing cartilage defects in the knee. The Company's products are used in a wide variety of applications including orthopedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information, visit www.collagensolutions.com
Enquiries:
Collagen Solutions Plc Contact via Walbrook Jamal Rushdy, Chief Executive Officer Gill Black, Chief Financial Officer Cenkos Securities plc (Nominated Tel: 0207 397 8900 Adviser and Broker) Stephen Keys Steve Cox Walbrook PR Tel: 020 7933 8780 or collagen@walbrookpr.com Mike Wort Mob: 07900 608 002 Anna Dunphy Mob: 07876 741 001
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTIIMATMBJTBIR
(END) Dow Jones Newswires
April 25, 2017 02:00 ET (06:00 GMT)
1 Year Collagen Solutions Chart |
1 Month Collagen Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions